Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1 Meeting Abstract
| Authors: | Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; Basu, C.; Skoura, A.; Chan, E. M.; Trudel, S.; Jakubowiak, A. J.; Gasparetto, C.; Chu, M.; Dalovisio, A. P.; Sebag, M.; Lesokhin, A. M. |
| Abstract Title: | Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1 |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.e20021 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: e20021 -- Meeting was also available virtually -- Source: Cinahl |
